[Hiring] Director, US Medical Affairs, NSCLC @Revolution Medicines

Role Description

The Director, US Medical Affairs – Non-Small Cell Lung Cancer (NSCLC) will support the development of the US medical strategy and lead execution of assigned medical priorities across the NSCLC portfolio. The role spans first-line and subsequent-line treatment settings and includes:

• Pre-launch planning
• Launch readiness
• Post-approval medical activities
• Lifecyle planning

As a member of the US Medical Affairs Team (USMAT), the Director will:

• Translate evolving clinical evidence, external expert perspectives, and field insights into focused medical objectives and actionable plans.
• Serve as an NSCLC scientific expert and partner across various teams including US and Global Medical Affairs, Field Medical, Clinical Development and Operations, Medical Information and Communications, HEOR/RWE, Biomarker and Companion Diagnostics, Commercial, Market Access, Patient Advocacy, Regulatory, Safety, Legal, and Compliance.

The ideal candidate will:

• Bring strong lung cancer expertise, scientific rigor, and hands-on Medical Affairs experience.
• Communicate complex evidence clearly, influence across functions, and manage multiple priorities in a fast-paced environment.

Key responsibilities include:

• Contributing to the US NSCLC medical strategy and annual portfolio plan; leading assigned tactics with clear objectives, timelines, budgets, and measures of impact.
• Conducting evidence and practice-gap assessments, incorporating US treatment patterns, stakeholder needs, competitive developments, and field insights to refine medical priorities.
• Supporting launch readiness, launch execution, and lifecycle planning across NSCLC assets in alignment with US and Global Medical Affairs strategies.
• Leading or supporting scientific engagement with US external experts through advisory boards, investigator interactions, congress activities, and peer-to-peer scientific exchange.
• Partnering with US Field Medical on scientific priorities, insight-generation plans, training, and resources that support high-quality scientific exchange.
• Synthesizing insights from external experts, field teams, advisory boards, and congresses; communicating implications and recommending actions to internal stakeholders.
• Serving as an NSCLC medical content expert on cross-functional teams, providing scientifically balanced input into US strategic discussions and decisions.
• Partnering with HEOR/RWE, Clinical Development, and Biomarker/Companion Diagnostics teams on evidence-generation priorities.
• Collaborating with Clinical Development, Clinical Operations, and Field Medical to support protocol review, site and investigator engagement, and appropriate trial awareness and enrollment activities.
• Contributing to publication, congress, medical communications, and data-disclosure plans; developing or reviewing scientific presentations, abstracts, manuscripts, educational content, and medical information response documents.
• Providing medical leadership for assigned US congress activities, scientific symposia, advisory boards, and internal education, ensuring scientific accuracy and consistency.
• Partnering with Patient Advocacy to incorporate patient and caregiver perspectives, and with Grants teams to identify priorities for independent medical education.
• Collaborating with Safety and Clinical teams on education and scientific exchange concerning adverse-event recognition and management in NSCLC.
• Managing assigned vendors and resources, tracking execution and outcomes, and conducting all activities in accordance with applicable requirements, company policies, and Revolution Medicines Core Values.

Qualifications

• Advanced clinical or scientific degree such as PharmD, PhD, MD, DO, or equivalent.
• 10+ years of relevant experience in biotechnology or pharmaceutical Medical Affairs and/or clinical oncology practice, including substantive hands-on Medical Affairs experience.
• Strong scientific background in lung cancer, with direct NSCLC experience and an understanding of biomarker-driven treatment and the US treatment landscape.
• Demonstrated ability to analyze, synthesize, and communicate complex clinical evidence with scientific accuracy and appropriate balance.
• Hands-on experience across core Medical Affairs activities, including medical planning, external expert engagement, field medical partnership, medical communications, evidence generation, congresses, advisory boards, and training.
• Demonstrated ability to collaborate and influence across functions, manage multiple projects and stakeholders, and deliver against agreed priorities.
• Excellent written, verbal, and presentation skills, with sound judgment and a commitment to ethical scientific exchange.
• Ability to travel approximately 30–40% for external expert engagements, medical congresses, and internal meetings, including visits to Redwood City headquarters.

Preferred Skills

• Established relationships with US thoracic oncology experts, investigators, and multidisciplinary care stakeholders in academic and community settings.
• Experience supporting US oncology launch readiness, launch execution, or post-launch medical strategy.
• Experience in precision oncology, RAS biology, targeted therapies, molecular testing, and companion diagnostics.
• Experience supporting clinical-trial strategy or execution, including protocol review, site engagement, enrollment support, and clinical data interpretation.
• Experience contributing to guideline or compendium submissions, such as NCCN, and collaborating with Global Medical Affairs on integrated medical and evidence-generation plans.

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities

Company Description

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing, and delivering innovative medicines for patients with RAS-addicted cancers. The company is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.